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ABSTRACT 
 
Adverse effects associated with sodium nitroprusside (SNP) administration are rarely observed in 
children. Monitoring of metabolic changes appears to be the most sensitive and accurate indicator 
of early toxicity. We report a case of acute toxicity in a 3-month-old boy treated with high-dose SNP 
infusion for systemic hypertension after elective coarctectomy, who developed seizures and severe 
lactic acidosis. We suggest blood lactate levels and base excess levels should be carefully 
monitored during SNP treatment in children, in order to detect early signs of toxicity, particularly 
when using high infusion rates. 
Case Study 
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1. INTRODUCTION 
 
Sodium nitroprusside (SNP) is an NO-releasing 
vasodilator and is used in infants and children in 
the management of systemic hypertension and to 
reduce after-load following cardiac surgery [1,2]. 
However, when used in large doses, SNP and its 
metabolic products, cyanide (CN) and 
thiocyanate (SCN), may induce severe toxicity 
causing vomiting, bradycardia, hypotension, 
seizures, apnea, coma and death, associated 
with metabolic acidosis and increased lactate 
levels.  
 
We report on an infant who suffered generalized 
seizures and severe metabolic acidosis during 
high-dose SNP therapy.  
 
2. CASE REPORT 
 
A 3-month-old boy, born at term with no 
congenital syndromes, developed severe 
systemic hypertension after a successful aortic 
coarctation repair. SNP infusion was started at 
0.3 gkg
-1
min
-1
 and progressively titrated up to 
8 gkg
-1
min
-1 
to maintain a systolic blood 
pressure  110 mmHg. At 28 hours 
postoperatively the patient was transferred from 
the Cardiac Intensive Care Unit to our PICU in 
good conditions, with stable hemodynamics, 
arterial blood pressure 100/45 mmHg, pH=7.46, 
PaO2 110 mmHg, PaCO2 25 mmHg, BE=-5 
mmoll-1 and lactate= 12 mmoll-1. Two hours 
later, due to his satisfactory clinical conditions 
and despite the high lactate levels, the patient 
was weaned off mechanical ventilation with 
normal chest and neurological examination. 
Markers of liver and renal function were within 
normal limits. About three hours later, despite a 
normal heart rate and a systolic blood pressure 
of 110 mmHg, systemic perfusion rapidly 
deteriorated, with mottling, prolonged capillary 
refill, obnubilation and onset of generalized 
seizures. Blood gas analysis revealed severe 
metabolic acidosis (pH=7.22, PaO2 72 mmHg, 
paCO2=25 mmHg, BE=-16 mmoll
-1, lactate 18.7 
mmoll-1). In the suspect of related toxicity, SNP 
infusion was discontinued, followed by a rapid 
clinical improvement. No other specific 
interventions were performed. A cardiac 
ultrasound evaluation was obtained urgently, 
showing normal heart function and a satisfactory 
aortic coarctation repair. At two and five hours 
since SNP discontinuation, lactate levels 
decreased to 10.2 and 6 mmoll
-1
, respectively, 
returning within normal range by the seventh 
hour. The patient was discharged 12 days later in 
good clinical conditions, with normal systemic 
blood pressure and no pharmacological 
treatment.  
 
3. DISCUSSION 
 
This study emphasizes the risk of toxicity in 
patients treated with high-dose SNP infusion. 
Adverse effects associated with SNP 
administration are rarely observed in children. In 
four reported cases, one patient died, [3] three 
others had cardiovascular collapse and 
temporary blindness [4-6]. The onset of toxicity 
occurred from 80 minutes to 60 hours since 
initiation of SNP, maximum infusion rates ranged 
from 5 to 12 gkg
-1
min
-1
, and tachyphylaxis 
often heralded the onset of serious cyanide 
toxicity [3-6]. 
 
SNP toxicity occurs because CN hampers 
oxygen tissue release, causing cellular hypoxia 
and anaerobic metabolism [1,7]. Controversy 
exists about the SNP dose more likely to cause 
toxicity: 0.5-10.0 gkg-1min-1 infusion rates and 
0.5-5 mgkg
-1
 total SNP doses have been 
reported as safe [1,8-10]. 
 
SNP toxicity relates more with infusion rate 
rather than with the total amount given. Amounts 
up to 1488 mg given continuously over a period 
of 12-314 hours did not cause toxicity, [1,7,9] 
whereas 400 mg given over 80 minutes were 
fatal [3]. SNP infusions above 10 gkg-1min-1 
can produce adverse metabolic and clinical 
effects [10]. Thus, maximum rate for long-term 
SNP infusion should be less than 8 gkg-1min-
1, possibly close to 4 gkg-1min-1, while 
maximum total SNP dose should not exceed 70 
mgkg-1 in periods shorter than 14 days. [9] Of 
notice Moffett and Price reported that even a 
dose of 1.8 gkg-1min-1 of SNP had a high 
sensitivity and specificity to predict elevated 
cyanide levels in a cohort of children who 
underwent cardio-thoracic surgery [11]. Patients 
undergoing cardiopulmonary bypass or 
hypothermia, treated with diuretics, 
malnourished, with hepatic or renal failure may 
be at greater risk owing to an impaired cyanide 
detoxification capability. Moreover infants may 
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have immature enzyme systems or lack of 
thiosulphate stores that may lead to toxicities 
[11]. Actually, coarctation repair in our patient, 
performed via lateral thoracotomy, was an off 
pump operation, i.e. neither cardiopulmonary 
bypass nor hypothermia were needed. 
 
Diagnosis of SNP related toxicity relies on non-
specific signs, such as nausea, vomiting, 
seizures, dyspnea or tachypnea, [12] often 
associated with metabolic acidosis, increased 
lactate or base deficit and altered mixed venous 
oxygen tension. Other specific investigations, 
namely red blood cell cyanide content, plasma 
cyanide and thiocyanate concentrations, usually 
are not readily available. Monitoring of metabolic 
changes (lactic acidosis, base deficits, increased 
mixed venous oxygen) appears to be the most 
sensitive and accurate indicators of early toxicity 
[2,11]. For decades SNP has been a popular 
drug for its rapid, powerful effect and the very 
short half-life. However, particularly when high 
doses are used, or hepatic and/or renal 
dysfunction are present, SNP may cause severe 
adverse events, due to accumulation of cyanide 
and its metabolites. In retrospect, the early onset 
of tachyphylaxis observed in our patient, which 
required an escalation of SNP doses, could have 
been interpreted as a risk factor for impending 
SNP-related toxicity, [5] suggesting either the 
use of alternative anti-hypertensive drugs for 
managing systemic blood pressure, or at least a 
combination with other agents, allowing decrease 
of the dose and/or duration of SNP treatment. 
Furthermore, sodium thiosulfate may have been 
added to the SNP infusion to prevent elevated 
cyanide concentrations and reduce the risk of 
poisoning.  
 
On the other hand, severe clinical signs 
associated with SNP toxicity were not anticipated 
by relevant metabolic changes. In fact, despite 
some discrepancy between a normal pH and a 
mildly altered base excess (BE) value (7.46 and -
5 mmoll-1, respectively) and a relatively high 
lactate (12 mmoll-1), metabolic acidosis and 
marked base deficit became apparent only after 
30 hours of SNP infusion, possibly delaying the 
diagnosis. Nonetheless, the already high lactate 
level observed on admission, despite a normal 
pH value which was probably due to the 
compensatory decrease of CO2, maybe should 
have prompted an earlier discontinuation of SNP 
therapy. 
 
The phenomenon we observed in our patient, 
about the striking discrepancy between normal 
blood pressure and normal heart rate vs 
prolonged capillary refill, mottling and altered 
mental status, remains to be further elucidated.  
A better scrutiny of initial lactate and base 
excess levels might have been decisive in early 
disclosing of metabolic derangements in our 
patient, prompting a modification of therapy. 
 
Cyanide and thiocyanate levels were not 
included in our initial diagnostic work-up since 
not readily available. Unfortunately, serum 
samples were not preserved for further analysis 
of cyanide toxicity. Nonetheless, we believe the 
suspected diagnosis of SNP toxicity was 
reinforced by the rapid improvement observed 
once the SNP infusion was suspended, and by 
the fact no further treatment was required. 
 
In theory, the occurrence of generalized seizures 
may have somehow contributed to the increase 
of lactate levels. In fact, early experiences in 
adults indicated a rise of lactate levels even after 
short “grand mal seizures”, of 30 to 60 seconds’ 
duration [13]. Then, although the seizure episode 
was veryshort in our case and did not require 
pharmacological treatment, we cannot exclude 
some additional effects on lactate accumulation.  
 
Of note, the presented case was thoroughly 
discussed at subsequent multidisciplinary 
meetings and the practice of transferring infants 
with IV infusion of SNP was thereafter nearly 
discontinued in our centre. In fact, at present we 
are using SNP less frequently for severe 
systemic hypertension, preferring other drugs 
such as esmolol, which has a safer profile.  
 
4. CONCLUSION 
 
In conclusion, we report a case of acute toxicity 
in a young infant treated with SNP infusion for 
systemic hypertension after elective 
coarctectomy, who developed seizures and 
severe lactic acidosis. Clinical signs were not 
apparent until metabolic and lactic acidosis 
reached extreme values. In order to detect early 
signs of toxicity, we suggest blood lactate and 
base excess levels should be strictly monitored 
during SNP treatment in children, particularly 
when high infusion rates are required and when 
prompt measurement of blood cyanide 
concentration is not available. 
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